Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsMiguel Sanmamed, MD, PhD
Assistant Professor AdjunctAbout
Research
Publications
2025
Association of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with response to atezolizumab in a Real-World-Evidence biomarker study for advanced urothelial carcinoma patients
de Andrea C, Abengozar-Muela M, Arranz J, Climent M, Puente J, Vizcay Á, de la Fuente L, Jurado J, Bonfill T, Santander C, Villa J, Pujol E, Rosero A, Gomez J, Fernández E, Fernández C, Ramirez I, Arnáiz P, López-Janeiro Á, Melero I, Sanmamed M, Pérez-Gracia J. Association of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with response to atezolizumab in a Real-World-Evidence biomarker study for advanced urothelial carcinoma patients. OncoImmunology 2025, 14: 2538687. PMID: 40778981, DOI: 10.1080/2162402x.2025.2538687.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntigens, CDBiomarkers, TumorCD8-Positive T-LymphocytesFemaleHepatitis A Virus Cellular Receptor 2HumansLymphocyte Activation Gene 3 ProteinMaleMiddle AgedProgrammed Cell Death 1 ReceptorTumor MicroenvironmentUrinary Bladder NeoplasmsConceptsAdvanced urothelial cancerMultiplexed quantitative immunofluorescenceTumor microenvironmentT cellsClinical efficacyPD-1LAG-3Tim-3Urothelial cancerPredictive biomarkersReal-world evidenceDistribution of CD8+ T cellsQuantitative immunofluorescenceCD8+ T-cell densityAdvanced urothelial carcinoma patientsAssociation of PD-1Intratumoral CD8 T cellsPatients treated with atezolizumabPre-treatment tumor samplesCD8+ T cellsPD-1/PD-L1 pathwayHundred-nine patientsPD-L1 blockadeResponse to atezolizumabCD8 T cellsDasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy.
Redin E, Otegui N, Santos M, Leon S, Redrado M, Serrano D, Fernandez de Pierola E, Russo-Cabrera J, Ferrer I, Olmedo M, Diaz-Lagares A, Houry M, Vicent S, Vilalta A, Mondelo-Macía P, García-González J, León-Mateos L, Gonzalez A, Paz-Ares L, López R, Sanmamed M, Montuenga L, Calvo A. Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy. Cancer Research 2025 PMID: 40712061, DOI: 10.1158/0008-5472.can-24-2772.Peer-Reviewed Original ResearchSmall cell lung cancerAntigen presenting cellsAnti-PD-1Cell lung cancerT cellsTumor infiltrationNatural killerNK cellsAntitumor efficacyLung cancerReduction of regulatory T cellsLonger progression-free survivalInfiltration of CD4+CD8+ T cellsCD4+ T cellsSmall cell lung cancer modelSmall cell lung cancer cellsTreg cell conversionImmune checkpoint blockadeAssociated with poor prognosisProgression-free survivalImmunotherapy-treated patientsTumor mutational burdenRegulatory T cellsCD4+ lymphocytesErratum: BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203
Márquez-Rodas I, Dutriaux C, Saiag P, de la Cruz Merino L, Castañón Álvarez E, Robert C, Rodríguez-Moreno J, Arance A, Cerezuela-Fuentes P, Montaudié H, Sanmamed M, González-Cao M, Charles J, López Criado M, Berrocal A, de Miguel E, Funck-Brentano E, Prey S, Álamo de la Gala M, Melero I, Avilés-Izquierdo J, Roman R, Garcia-Pelaez B, Rodriguez S, Trnkova Z, Quintero M, Maciá S, Chaney M, Dalle S. Erratum: BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203. Journal Of Clinical Oncology 2025, 43: 2840-2840. PMID: 40706004, DOI: 10.1200/jco-25-01680.Peer-Reviewed Original ResearchPhase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas
Wermke M, Gambardella V, Kuboki Y, Felip E, Sanmamed M, Alese O, Sayehli C, Arriola E, Wolf J, Villaruz L, Bertulis J, Studeny M, Bouzaggou M, Fang X, Morgensztern D. Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas. Journal Of Clinical Oncology 2025, 43: 3021-3031. PMID: 40706016, PMCID: PMC12440289, DOI: 10.1200/jco-25-00363.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerMaximum tolerated doseOverall response rateStep-up dosingCell lung cancerNeuroendocrine carcinomaFixed doseTarget doseAnti-PD-1/PD-L1 therapyLung cancerTreatment-related adverse eventsExtrapulmonary neuroendocrine carcinomasCell neuroendocrine carcinomaDose-limiting toxicityT-cell engagersCytokine release syndromeMinimum effective doseRECIST v1.1Tumor responseMedian durationTumor typesAdverse eventsDose onceRegimensAnticancer therapyLifileucel tumor‐infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors
Kluger H, Grigoleit G, Thomas S, Domingo‐Musibay E, Chesney J, Sanmamed M, Medina T, Ziemer M, Whitman E, Finckenstein F, Gastman B, Chou J, Wu X, Sulur G, Fiaz R, Qi R, Sarnaik A. Lifileucel tumor‐infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors. Cancer Communications 2025 PMID: 40693376, DOI: 10.1002/cac2.70050.Peer-Reviewed Original ResearchBO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203
Márquez-Rodas I, Dutriaux C, Saiag P, de la Cruz Merino L, Álvarez E, Robert C, Rodríguez-Moreno J, Arance A, Cerezuela-Fuentes P, Montaudié H, Sanmamed M, González-Cao M, Charles J, Criado M, Berrocal A, de Miguel E, Funck-Brentano E, Prey S, de la Gala M, Melero I, Avilés-Izquierdo J, Roman R, Garcia-Pelaez B, Rodriguez S, Trnkova Z, Quintero M, Maciá S, Chaney M, Dalle S. BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203. Journal Of Clinical Oncology 2025, 43: 2806-2815. PMID: 40577656, PMCID: PMC12393066, DOI: 10.1200/jco-24-02595.Peer-Reviewed Original ResearchConceptsProgression-free survivalDuration of responsePhase II clinical trialBO-112Primary end pointOverall survivalEnd pointsClinical trialsAnti-PD-1 resistanceMedian duration of responseMedian progression-free survivalProgression-free survival resultsNo deaths related to treatmentIntention-to-treat populationDeaths related to treatmentAnti-PD-1Central radiology reviewIntravenous pembrolizumabStable diseaseAdvanced melanomaProgressive diseaseRadiological reviewSolid tumorsPembrolizumabAdverse eventsEfficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial.
Capdevila J, Gambardella V, Kuboki Y, Alese O, Morgensztern D, Sayehli C, Sanmamed M, Arriola E, Studeny M, Bouzaggou M, Chen Z, Lifke V, Wolf J, Wermke M. Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial. Journal Of Clinical Oncology 2025, 43: 3004-3004. DOI: 10.1200/jco.2025.43.16_suppl.3004.Peer-Reviewed Original ResearchDelta-like ligand 3Disease control rateExtrapulmonary neuroendocrine carcinomasNeuroendocrine carcinomaMedian DORDose escalationImmune effector cell-associated neurotoxicity syndromeDose-escalation regimensDose-escalation trialDuration of responseT-cell engagersCytokine release syndromePhase I trialRECIST v1.1Systemic therapyI trialBaseline characteristicsNeurotoxicity syndromeSafety profileStandard treatmentControl rateTumor cellsEfficacy dataDisease progressionResponse rateCo-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors
Senent Y, Fresquet V, Jiménez V, Valencia K, Exposito F, Martín-Úriz P, Camps G, Fernández-Pierola E, de Córdoba B, González-Huarriz M, Tamayo I, Remírez A, Moreno H, Serrano D, Ajona D, Alonso M, Lecanda F, Pineda-Lucena A, Prósper F, Sanmamed M, Calvo A, Martinez-Climent J, Pio R. Co-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors. Molecular Cancer 2025, 24: 154. PMID: 40442785, PMCID: PMC12123720, DOI: 10.1186/s12943-025-02352-4.Peer-Reviewed Original ResearchConceptsImmune checkpoint blockadeBcl-xL inhibitorsBcl-xLSolid tumorsTumor cell linesHematologic malignanciesSolid tumor cell linesEfficacy of immune checkpoint blockade therapyEpigenetic regulationImmune checkpoint blockade therapyAnti-apoptotic protein Bcl-xLHuman colon cancer modelsPreclinical models of solid tumorsBCL-XL dependencyImmunosuppressive Treg cellsCheckpoint blockade therapyAnti-tumor responsesImmunogenic cell deathProlonged overall survivalProtein Bcl-xLColon cancer modelM1/M2 macrophage ratioMultiple solid tumorsModels of solid tumorsCell linesA Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid Tumors
Bechter O, Loquai C, Champiat S, Baurain J, Grob J, Utikal J, Rottey S, Berrocal A, Hassel J, Arance A, Sanmamed M, Boers-Sonderen M, Gastman B, Gebhardt C, Delafontaine B, Sahin U, Türeci Ö, Brueck P, Abbadessa G, Marpadga R, Lee H, Yang Y, Buday B, Di Genova G, Wang H, Xia B, Lee J, Lebbe C. A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid Tumors. Clinical Cancer Research 2025, 31: 2358-2369. PMID: 40152791, PMCID: PMC12163594, DOI: 10.1158/1078-0432.ccr-24-1983.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCytokinesFemaleGranulocyte-Macrophage Colony-Stimulating FactorHumansInterferon alpha-2Interleukin-12Interleukin-15MaleMaximum Tolerated DoseMiddle AgedNeoplasmsRNA, MessengerTreatment OutcomeConceptsAdvanced solid tumorsMaximum administered doseSolid tumorsCombination therapyEscalation phaseTreated with anti-PD-1 therapyTreated with anticancer therapyAnti-PD-1 therapyTreatment-related adverse eventsDose level 8Predefined dose levelsInjection-site painFirst-in-humanPlasma cytokine concentrationsDose escalationAntitumor responsePartial responseIntratumoral administrationExpansion trialIL-15IFN-gCemiplimabAdverse eventsCytokine concentrationsDose levelsSafety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
Gambardella V, Ong M, Rodriguez-Ruiz M, Machiels J, Sanmamed M, Galvao V, Spreafico A, Renouf D, Luen S, Galot R, de Spéville B, Calvo E, Naing A, Curdt S, Kolben T, Rossmann E, Tanos T, Smart K, Amann M, Xie Y, Xu L, Alcaide E, Städler N, Justies N, Boetsch C, Karanikas V, Schnetzler G, Rohrberg K. Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors. Cancer Research Communications 2025, 5: 422-432. PMID: 39983024, PMCID: PMC11891644, DOI: 10.1158/2767-9764.crc-24-0638.Peer-Reviewed Original ResearchConceptsRecommended phase II dosePhase II doseMaximum tolerated dosePhase I studyTreg depletionSolid tumorsII doseTolerated doseResistance to cancer immunotherapyRegulatory T-cell depletionImmunosuppressive regulatory T cellsEffector T cell functionAdvanced solid tumorsT-cell depletionRegulatory T cellsAnti-CD25 antibodyFrequent adverse eventsT cell functionDose-dependent depletionIL-2 signalingAtezolizumab combinationDeplete TregsTreg reductionDose escalationPeripheral Tregs